Intrexon Corporation (XON) : Zacks Investment Research ranks Intrexon Corporation (XON) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 7 research analysts is 1.86, which indicates as a Buy.
Intrexon Corporation (XON) : Average target price received by Intrexon Corporation (XON) is $46.88 with an expected standard deviation of $11.18. The most aggressive target on the stock is $57, whereas the most downbeat target is $29. 8 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy.
Intrexon Corporation (NYSE:XON): The stock opened at $26.70 on Tuesday but the bulls could not build on the opening and the stock topped out at $26.73 for the day. The stock traded down to $25.85 during the day, due to lack of any buying support eventually closed down at $25.89 with a loss of -1.30% for the day. The stock had closed at $26.23 on the previous day. The total traded volume was 1,107,396 shares.
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.